Mr Nick Duncan MRPharmS, MSc

Mr Nick Duncan

School of Pharmacy
Academic Practitioner

Contact details

Address
Institute of Clinical Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Nick is an Academic Practitioner and is part of the team developing the Pharmacy Programmes within the College of Medical and Dental Sciences. He teaches oncology and haematology on the M Pharm course in addition to inputing into the MSc in Clinical Oncology

Nick is a hospital pharmacist with considerable experience in the fields of oncology and haematology, particularly in the area of haematopoietic stem cell transplantation.   He is enthusiastic about promoting multidisciplinary working in the management of cancer patients and has a special interest in providing educational inputs to encourage optimal adherence in patients taking oral anticancer medicines.

Nick is keen on developing inter-professional working, teaching and learning practices. Other areas of interest include medicines adherence, antifungal stewardship and the pharmaceutical care of patients receiving chemotherapy.

Qualifications

  • Practice Certificate in Independent Prescribing 2010
  • MSc in Clinical Oncology 2004
  • Postgraduate Diploma in Pharmacy Practice 1996
  • Member of the Royal Pharmaceutical society 1994
  • BPharm 1993

Biography

Nick Duncan gained a BPharm from The University of Nottingham in 1993 and subsequently obtained an MSc in Clinical Oncology from the University of Birmingham.  He has spent most of his career to date working in oncology and haematology, initially at the Royal Marsden Hospital in Sutton and, since 1999, at the University Hospitals Birmingham NHS Foundation Trust.   

In 2010 he was awarded a fellowship of the Faculty of Cancer Pharmacy and the College of Pharmacy Practice and in 2015 became a Fellow of the Faculty of the Royal Pharmaceutical Society.  He qualified as an independent prescriber in 2010 and has a varied prescribing role in both oncology and haematology clinics.  He is an active member of the British Oncology Pharmacy Association (BOPA) and is a regular presenter at their annual symposium.   In 2016 he became the first consultant pharmacist in haematology/oncology in the West Midlands. 

Teaching

Postgraduate supervision

Nick’s areas of research interest are:

  • Pharmaceutical Care
  • Clinical Pharmacy
  • Medicines Adherence

Research

Nick’s research interests include promoting adherence to oral anticancer medicines, antifungal stewardship and the supportive care of haematology patients undergoing haematopoietic stem cell transplantation.

Publications

Duncan N. Lymphomas: current and future treatment options.  Clinical Pharmacist 2014; 6: 

Duncan N. Lymphomas: pathogenesis, clinical features and diagnosis.  Clinical Pharmacist 2014 6: 

Duncan N. Treating acute myeloid leukaemia in the elderly. Hospital Pharmacy Europe 2013; 70: 39-41 

Duncan N.  Multiple myeloma.  Clinical features and classification.  Clinical Pharmacist 2012; 4: 123-126 

Duncan N.  Multiple myeloma.  Management.  Clinical Pharmacist 2012; 4: 127-132 

Duncan N.  Adult Myeloid Leukaemias: pathogenesis, clinical features and classification.  Clinical Pharmacist 2010; 2: 117-121 

Duncan N.  Adult Myeloid Leukaemias: current and future treatments.  Clinical Pharmacist 2010; 2: 122-127 

Duncan N, Arrazi J, Nagra S, Cook M, Thomson AH, Craddock C. Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation.  Ther Drug Monit. 2010; 32: 353-8. 

Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N.  Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2010; 95: 989-95. 

Craddock C, Anson J, Chu P, Dodgson A, Duncan N, Gomez C, Mehta J, Sadullah S, Subudhi C, Yin JL.  Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex.  Expert Opin Drug Saf. 2010; 9: 139-47 

Duncan N.  Stem cell transplantation in multiple myeloma.  Hospital Pharmacy Europe 2009; 42; 52-55 

Duncan N, Craddock C.  Optimizing the use of cyclosporin in allogeneic stem cell transplantation.  Bone Marrow Transplant 2006; 38: 169-74 

K Raj, S Narayanan, B Augustson, A Ho, P Mehta, N Duncan, S Tauro, P Mahendra, C Craddock, G Mufti.  Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.  Bone Marrow Transplant 2005: 35; 299-301 

Tauro S, Shankaranarayana P, Nitu-Whalley IC, Duncan N, Begum G, Craig JI, Marcus RE,  Craddock CF, Mahendra P. Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. Bone Marrow Transplant 2003; 32: 273-8. 

Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N, Mahendra P.  Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure.  Bone Marrow Transplant 2002; 30: 471-3 

Duncan N, Hewetson M, Atra A, Dick G, Pinkerton R.  An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children.  Pharmacoeconomics 1997; 11: 169-74 

Duncan N, Hewetson M, Powles R, Raje N, Mehta J.  An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma.  Bone Marrow Transplant 1996; 18: 1175-8 

Thomson AH, Duncan N, Silverstein B, Alcock S, Jodrell D.  Development of guidelines for gentamicin dosing.  Journal of Antimicrobial Chemotherapy 1996; 38: 885-93 

Duncan N, Richardson J.  How to make leaflets readable.  Hospital Pharmacy Practice 1994; 4: 97-100